Avanafil for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Avanafil for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Avanafil is a fast-acting prescription medication for erectile dysfunction, in the same drug family as sildenafil and tadalafil. It reliably improves erections, including in men with diabetes or after prostate surgery; effects start quickly and fade within hours. Common side effects are usually mild: headache, flushing and nasal congestion. Combined with heart medications called nitrates, it can cause dangerous blood-pressure drops. Its role in longer-term health remains uncertain. (Full Review)

Protocol

Standard on-demand dosing
100 mg
About 15 minutes before sexual activity; adjusted to 200 mg or down to 50 mg (taken 30 minutes before)
Single versus split dosing
No more than once in 24 hours
Taken as a single dose; splitting a dose offers no advantage
Food timing
Empty stomach or light meal
A high-fat meal delays peak levels by about an hour
Time to effect
Time to effect
About 15 minutes
Lasts up to roughly 6 hours; response typically judged over several attempts at a given dose
Half-life
Near 5 hours
Peak levels at 30–45 minutes; most effect is gone by the next day
Cycling
Not needed
Efficacy held over 52 weeks without tolerance

Benefits

Contraindications
  • Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate; if medically necessary, at least 12 hours after the last avanafil dose, under close medical supervision)
  • Recreational nitrates ("poppers," amyl nitrite)
  • Guanylate cyclase stimulators (riociguat, vericiguat)
  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone)
  • Heart attack, stroke, life-threatening arrhythmia or coronary revascularization (stent or bypass) within the past 6 months
  • Resting hypotension below 90/50 mmHg or uncontrolled hypertension above 170/100 mmHg
  • Unstable angina, angina during intercourse, or heart failure NYHA Class II or higher
  • Left ventricular outflow obstruction (severe aortic stenosis, hypertrophic obstructive cardiomyopathy)
  • Severe kidney impairment (creatinine clearance below 30 mL/min) or dialysis
  • Severe liver impairment (Child-Pugh Class C)
  • Hereditary degenerative retinal disorders (retinitis pigmentosa)
  • Known hypersensitivity to avanafil
    •
Key Interactions
  • Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil, aprepitant; maximum 50 mg once per 24 hours)
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin)
  • Alpha-blockers (doxazosin, terazosin, tamsulosin, alfuzosin; starting at 50 mg)
  • Blood-pressure medications (amlodipine, enalapril)
  • Other PDE5 inhibitors (sildenafil, tadalafil, vardenafil, including formulations for pulmonary hypertension)
  • Cimetidine
  • Unregulated "male enhancement" products
  • St. John's wort
  • Goldenseal and berberine
  • Yohimbine
  • Supplements with additive blood-pressure lowering (L-arginine, L-citrulline, beetroot nitrate, hawthorn, garlic extract)
  • Alcohol (above 3 standard drinks around dosing)
  • Grapefruit juice
  • Sauna, hot tubs and intense heat (within a few hours of dosing)
    •

Risk & Side Effects

  • High: Headache, flushing, and nasal congestion; low blood pressure, especially with nitrates
    •
  • Medium:
  • Low: Conflicted evidence for sudden vision loss; sudden hearing loss; priapism; conflicted evidence for melanoma; rise in HbA1c in type 2 diabetes; heart attack, stroke and sudden cardiac death
    •
  • Speculative: Masking of underlying cardiovascular disease
    •

Monitoring

Marker Target Why
Blood pressure (seated and standing) 110–120/70–80 mmHg; never below 90/50 Hypotension risk; vascular health
HbA1c 4.8–5.4% Predicts response; class glucose effect
ApoB Below 80 mg/dL (below 60 mg/dL if high risk) Atherosclerosis driving vascular dysfunction
Morning total testosterone 500–900 ng/dL Low levels blunt response
eGFR Above 90 mL/min/1.73 m² Severe kidney impairment excludes use
ALT Below 25 U/L Severe liver impairment excludes use
IIEF-5 questionnaire score 22–25 Tracks treatment response

Cadence: Baseline before starting; erectile response and side effects reassessed after about 4 weeks or 4–8 doses; blood pressure rechecked after each dose change; laboratory panel and questionnaire repeated every 6–12 months; new visual or hearing symptoms prompt immediate evaluation

Qualitative Assessment

  • Erection firmness and reliability across attempts
  • Time from dosing to adequate erection
  • Sexual confidence, satisfaction and partner satisfaction
  • Headache, flushing or nasal congestion frequency and severity
  • Any dizziness on standing after dosing
  • Any change in vision, color perception or hearing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.